Predicting unbound phenytoin concentrations in the critically ill neurosurgical patient

Annals of Pharmacotherapy

Volumn 30, Issue 3, 1996, Pages 219-223

  Mlynarek, Mark E ^a,b   Peterson, Edward L ^a   Zarowitz, Barbara J ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; SERUM ALBUMIN;

ACCURACY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; BRAIN ARTERY ANEURYSM; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; FEMALE; FLUORESCENCE POLARIZATION; HUMAN; HYPOPHYSIS TUMOR; INTENSIVE CARE UNIT; MALE; NEUROSURGERY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SEIZURE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA;

EID: 0029887802     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000301     Document Type: Article

References (19)

1. Hayes G, Kootsikas ME. Reassessing the lower end of the phenytoin therapeutic range: a review of the literature. Ann Pharmacother 1993;27:1389-92.
2. Zielman S, Mielck F, Kahl R, Kazmaier S, Sydow M, Kolk J, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit 1994;16:139-44.
3. Winter MG, Tozer TN. Chapter 25. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. Principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:1-44.
4. Boucher BA, Rodman JH, Jaresko GS, Rasmussen SN, Watridge CB, Fabian TC Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988;44:675-83.
5. Driscoll DF, McMahon M, Blackburn GL, Bistrian BR. Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations. Crit Care Med 1988;16:1248-9.
6. Levy RH, Schmidt D. Utility of free level monitoring of antiepileptic drugs Epilepsia 1985;26:199-205.
7. Lindow J, Wijdicks EFM. Phenytoin toxicity associated with hypoalbumincmia in critically ill patients. Chest 1994;105:602-4.
8. Gugler R, Azamoff DL, Shoeman DW. Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr 1975;53:445-6.
9. Beck DE, Farringer JA, Ravis WR, Robinson CA. Accuracy of three methods for predicting concentrations of free phenytoin. Clin Pharm 1987;6:888-94.
10. Mauro LS, Mauro VF, Bachmann KA, Higgins JT. Accuracy of two equations in determining normalized phenytoin concentrations. DICP Ann Pharmacother 1989;23:64-8.
11. Dasgupta A, Dennen DA, Dean R, McLawhon RW. Prediction of free phenytoin levels based on [total phenytoin]/[albumin] ratios. Potential errors with hypoalbuminemia. Am J Clin Pathol 1991;95:253-6.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatininc. Nephron 1976;16:31-41.
13. Cochran WG. Ratio sampling. In: Sampling techniques. 3rd ed New York: Wiley and Sons, 1977.150-86
14. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharm Biopharm 1981;9:503-12.
15. Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology 1984;34:395-7.
16. Coleman RW, Krewsun I, Kelber RL Single feedback Bayesian forecasts with free and total phenytoin concentrations. Clin Pharmacokinet 1984;9(suppl 1):90-2.
17. Lunde KM, Rane A, Yaffe SJ, Lund L, Sjoqvist F. Plasma protein binding of diphenylhydantoin in man: interaction with other drugs and the effect of temperature and plasma dilution. Clin Pharmacol Ther 1970;11:846-55.
18. Kinniburgh DW, Boyd ND. Phenytoin binding to partially purified albumin in renal disease. Clin Pharmacol Ther 1981;29:203-10
19. Allison TB, Comstock TJ. Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia. Ther Drug Monit 1988;10:376-81.